Apellis Pharmaceuticals Stock Price Prediction

APLS Stock  USD 34.14  1.51  4.63%   
At this time, the RSI of Apellis Pharmaceuticals' share price is approaching 44. This suggests that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Apellis Pharmaceuticals, making its price go up or down.

Oversold Vs Overbought

44

 
Oversold
 
Overbought
The successful prediction of Apellis Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Apellis Pharmaceuticals and does not consider all of the tangible or intangible factors available from Apellis Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Apellis Pharmaceuticals, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Apellis Pharmaceuticals' stock price prediction:
EPS Estimate Next Quarter
(0.20)
EPS Estimate Current Year
(1.67)
EPS Estimate Next Year
(0.86)
Wall Street Target Price
45.75
EPS Estimate Current Quarter
(0.30)
Using Apellis Pharmaceuticals hype-based prediction, you can estimate the value of Apellis Pharmaceuticals from the perspective of Apellis Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.

Apellis Pharmaceuticals Hype to Price Pattern

Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Apellis Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Apellis Pharmaceuticals.
The fear of missing out, i.e., FOMO, can cause potential investors in Apellis Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Apellis because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Apellis Pharmaceuticals after-hype prediction price

    
  USD 33.99  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Apellis Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.
Intrinsic
Valuation
LowRealHigh
30.7343.1246.63
Details
21 Analysts
Consensus
LowTargetHigh
65.2671.7179.60
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.45-0.42-0.39
Details

Apellis Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Apellis Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Apellis Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Apellis Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Apellis Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Apellis Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Apellis Pharmaceuticals' historical news coverage. Apellis Pharmaceuticals' after-hype downside and upside margins for the prediction period are 30.48 and 37.50, respectively. We have considered Apellis Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
34.14
33.99
After-hype Price
37.50
Upside
Apellis Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Apellis Pharmaceuticals is based on 3 months time horizon.

Apellis Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Apellis Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.14 
3.51
  0.15 
  0.05 
8 Events / Month
11 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
34.14
33.99
0.44 
319.09  
Notes

Apellis Pharmaceuticals Hype Timeline

Apellis Pharmaceuticals is presently traded for 34.14. The entity has historical hype elasticity of -0.15, and average elasticity to hype of competition of -0.05. Apellis is expected to decline in value after the next headline, with the price expected to drop to 33.99. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.44%, whereas the daily expected return is presently at -0.14%. The volatility of related hype on Apellis Pharmaceuticals is about 1061.34%, with the expected price after the next announcement by competition of 34.09. About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.03. Apellis Pharmaceuticals had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 8 days.
Check out Apellis Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Apellis Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Apellis Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Apellis Pharmaceuticals' future price movements. Getting to know how Apellis Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Apellis Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
RXDXPrometheus Biosciences 0.05 9 per month 0.76  0.10  2.76 (3.26) 70.71 
AKROAkero Therapeutics(0.28)9 per month 2.66  0.07  5.23 (4.45) 13.37 
IMVTImmunovant 0.74 8 per month 0.00 (0.08) 3.77 (5.06) 17.16 
MDGLMadrigal Pharmaceuticals(8.27)10 per month 2.13  0.08  5.17 (3.96) 30.27 
DAWNDay One Biopharmaceuticals(0.07)9 per month 0.00 (0.05) 3.84 (3.69) 11.44 
MRTXMirati Ther 0.00 0 per month 0.00 (0.18) 4.02 (4.07) 16.13 
AMLXAmylyx Pharmaceuticals 0.14 9 per month 4.07  0.27  10.06 (6.13) 33.56 
TERNTerns Pharmaceuticals 0.03 11 per month 0.00 (0.07) 6.02 (5.96) 34.09 
XFORX4 Pharmaceuticals 0.00 10 per month 0.00 (0.04) 8.82 (10.61) 62.35 
INZYInozyme Pharma(0.32)6 per month 0.00 (0.31) 5.07 (7.92) 16.62 
MREOMereo BioPharma Group 0.02 8 per month 0.00 (0.14) 4.80 (6.31) 17.36 
BPMCBlueprint Medicines Corp 3.17 9 per month 2.58 (0.02) 4.90 (3.62) 14.28 
CERECerevel Therapeutics Holdings 0.20 9 per month 0.94 (0.03) 1.91 (1.59) 6.40 
ABOSAcumen Pharmaceuticals(0.04)8 per month 0.00 (0.09) 7.52 (6.78) 28.07 

Apellis Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Apellis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Apellis using various technical indicators. When you analyze Apellis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Apellis Pharmaceuticals Predictive Indicators

The successful prediction of Apellis Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Apellis Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Apellis Pharmaceuticals based on analysis of Apellis Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Apellis Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Apellis Pharmaceuticals's related companies.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding55.437.39190.0199.5
PTB Ratio20.0932.336.5219.3

Story Coverage note for Apellis Pharmaceuticals

The number of cover stories for Apellis Pharmaceuticals depends on current market conditions and Apellis Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Apellis Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Apellis Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Apellis Pharmaceuticals Short Properties

Apellis Pharmaceuticals' future price predictability will typically decrease when Apellis Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Apellis Pharmaceuticals often depends not only on the future outlook of the potential Apellis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Apellis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding118.7 M
Cash And Short Term Investments352.3 M

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.